Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-27T19:54:14.796Z Has data issue: false hasContentIssue false
  • English
  • Français

How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins

Published online by Cambridge University Press:  16 April 2020

F.C.J. Starrenburg  and
J.P.A.M. Bogers
F.C.J. Starrenburg*
Affiliation:
Rivierduinen Psychiatric Centre, Midden Holland District, JP Thijsselaan 45, 2803RTGouda, Netherlands
J.P.A.M. Bogers*
Affiliation:
Rivierduinen Psychiatric Centre, Haagstreek District, PO Box 422, 2260AKLeidschendam, Netherlands
*
1Tel.: +31 182563700; fax: +31 182563726.
*Corresponding author. Tel.: +31 704441122; fax: +31 704441074. E-mail addresses: [email protected] (F. C. J. Starrenburg), [email protected] (J.P.A.M Bogers).
Get access

Abstract

The prevalence of Diabetes Mellitus (DM) is becoming a serious public health problem. The use of atypical antipsychotics has been associated with disruption of the glucose metabolism and therefore with causing DM. The underlying mechanisms are unknown, but knowledge of the differences between the pharmacological features of various antipsychotics combined with their diabetogenic profile might help us to understand those mechanisms. This article describes how the binding of various essential receptors or transporters in essential body tissues, adipose tissue, pancreatic tissue and liver and skeletal muscle tissue can cause disruption of the glucose metabolism. With such knowledge in mind one can try to explain the differences between the diabetogenic propensities of various antipsychotics. It is well known that clozapine and olanzapine cause weight gain and DM, whereas aripiprazole and ziprasidone have much less disruptive clinical profiles. The most significant risk factor for adiposity seems to be strong blocking of histaminergic receptors. An agonistic activity on serotonergic-1a receptors, with a very low affinity for muscarinergic-3 receptors, might protect against the development of DM. More data will become available which may help to solve the puzzle.

Keywords

Diabetes mellitusAntipsychoticsReceptor-bindingAdipocytokinesWeightGlucose
Type
Review
Information
European Psychiatry , Volume 24 , Issue 3 , April 2009 , pp. 164 - 170
Copyright
Copyright © Elsevier Masson SAS 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Altman, J.D., Trendelenburg, A.U., MacMillan, L., Bernstein, D., Limbird, L., Starke, K.et al.Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 1999 Jul;56(1):154–161CrossRefGoogle Scholar
Ardizzone, T.D., Bradley, R.J., Freeman, A.M.3rd Dwyer, D.S.Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res 2001 Dec 27;923(1–2):82–90CrossRefGoogle ScholarPubMed
Arranz, B., Rosel, P., Ramirez, N., Duenas, R., Fernandez, P., Sanchez, J.M.et al.Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004 Oct;65(10):1335–1342CrossRefGoogle Scholar
Auwerx, J., Staels, B.Leptin. Lancet 1998 Mar 7;351(9104):737–742CrossRefGoogle Scholar
Basile, V.S., Masellis, M., McIntyre, R.S., Meltzer, H.Y., Lieberman, J.A., Kennedy, J.L.Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001;23(Suppl. 62):45–66Google Scholar
Bergman, R.N., Ader, M.Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005 Apr;66(4):504–514CrossRefGoogle Scholar
Bjorbaek, C., El-Haschimi, K., Frantz, J.D., Flier, J.S.The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 1999 Oct 15;274(42):30059–30065CrossRefGoogle Scholar
Boehm, G., Racoosin, J.A., Laughren, T.P., Katz, R.Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 2004 Aug;27(8):2088–2089 author reply 9–90CrossRefGoogle Scholar
Cassidy, F., Ahearn, E., Carroll, B.J.Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999 Sep;156(9):1417–1420Google Scholar
Chang, J.S., Ahn, Y.M., Park, H.J., Lee, K.Y., Kim, S.H., Kang, U.G.et al.Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008 May;69(5):720–731CrossRefGoogle Scholar
Citrome, L., Jaffe, A., Levine, J., Allingham, B., Robinson, J.Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004 Sep;55(9):1006–1013CrossRefGoogle Scholar
Colli, A., Cocciolo, M., Francobandiera, F., Rogantin, F., Cattalini, N.Diabetic ketoacidosis associated with clozapine treatment. Diabetes Care 1999 Jan;22(1):176–177CrossRefGoogle Scholar
Ebenbichler, C.F., Laimer, M., Eder, U., Mangweth, B., Weiss, E., Hofer, A.et al.Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003 Dec;64(12):1436–1439CrossRefGoogle Scholar
E.M.E.A., EMEA. Scientific discussion Available from www.emea.europa.eu/humandocs/PDFs/EPAR/abilify/089304en6.pdf 2005;Google Scholar
Farooqi, I.S., Matarese, G., Lord, G.M., Keogh, J.M., Lawrence, E., Agwu, C.et al.Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002 Oct;110(8):1093–1103CrossRefGoogle Scholar
Gautam, D., Han, S.J., Hamdan, F.F., Jeon, J., Li, B., Li, J.H.et al.A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 2006 Jun;3(6):449–461CrossRefGoogle Scholar
Gianfrancesco, F.D., Grogg, A.L., Mahmoud, R.A., Wang, R.H., Nasrallah, H.A.Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002 Oct;63(10):920–930CrossRefGoogle Scholar
Gromada, J., Hughes, T.E.Ringing the dinner bell for insulin: muscarinic M3 receptor activity in the control of pancreatic beta cell function. Cell Metab 2006 Jun;3(6):390–392CrossRefGoogle Scholar
Hagg, S., Joelsson, L., Mjorndal, T., Spigset, O., Oja, G., Dahlqvist, R.Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998 Jun;59(6):294–299CrossRefGoogle Scholar
Hagg, S., Soderberg, S., Ahren, B., Olsson, T., Mjorndal, T.Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 2001 Nov;62(11):843–848CrossRefGoogle Scholar
Hanssens, L., van Winkel, R., Wampers, M., Van Eyck, D., Scheen, A., Reginster, J.Y.et al.A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008 Dec;106(2–3):308–314CrossRefGoogle Scholar
Havel, P.J.Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004 Feb;1(Suppl. 53):S143–S151CrossRefGoogle Scholar
Hayashi, A., Sonoda, R., Kimura, Y., Takasu, T., Suzuki, M., Sasamata, M.et al.Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats. Brain Res 2004 Jun 18;1011(2):221–227CrossRefGoogle Scholar
Henderson, D.C.Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001;23(Suppl. 62):39–44Google Scholar
Henderson, D.C., Cagliero, E., Copeland, P.M., Borba, C.P., Evins, E., Hayden, D.et al.Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005 Jan;62(1):19–28CrossRefGoogle Scholar
Howes, O.D., Bhatnagar, A., Gaughran, F.P., Amiel, S.A., Murray, R.M., Pilowsky, L.S.A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 2004 Feb;161(2):361–363CrossRefGoogle Scholar
Jackson, H.C., Needham, A.M., Hutchins, L.J., Mazurkiewicz, S.E., Heal, D.J.Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 1997 Aug;121(8):1758–1762CrossRefGoogle Scholar
Jeanrenaud, B.An hypothesis on the aetiology of obesity: dysfunction of the central nervous system as a primary cause. Diabetologia 1985 Aug;28(8):502–513CrossRefGoogle Scholar
Jindal, R.D., Keshavan, M.S.Critical role of M3 muscarinic receptor in insulin secretion: implications for psychopharmacology. J Clin Psychopharmacol 2006 Oct;26(5):449–450CrossRefGoogle Scholar
Johnson, D.E., Yamazaki, H., Ward, K.M., Schmidt, A.W., Lebel, W.S., Treadway, J.L.et al.Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005 May;54(5):1552–1558CrossRefGoogle Scholar
Kabinoff, G.S., Toalson, P.A., Healey, K.M., McGuire, H.C., Hay, D.P.Metabolic issues with atypical antipsychotics in primary care: dispelling the myths. Prim Care Companion J Clin Psychiatry 2003 Feb;5(1):6–14CrossRefGoogle Scholar
Kern, P.A., Ranganathan, S., Li, C., Wood, L., Ranganathan, G.Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001 May;280(5):E745–E751CrossRefGoogle Scholar
King, H., Aubert, R.E., Herman, W.H.Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 Sep;21(9):1414–1431CrossRefGoogle Scholar
Kopelman, P.G., Albon, L.Obesity, non-insulin-dependent diabetes mellitus and the metabolic syndrome. Br Med Bull 1997;53(2):322–340CrossRefGoogle ScholarPubMed
Kraus, T., Haack, M., Schuld, A., Hinze-Selch, D., Kuhn, M., Uhr, M.et al.Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999 Feb;156(2):312–314Google Scholar
Kroeze, W.K., Hufeisen, S.J., Popadak, B.A., Renock, S.M., Steinberg, S., Ernsberger, P.et al.H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003 Mar;28(3):519–526CrossRefGoogle Scholar
Laimer, M., Ebenbichler, C.F., Kranebitter, M., Eder, U., Mangweth, B., Weiss, E.et al.Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors. J Clin Psychopharmacol 2005 Apr;25(2):183–185CrossRefGoogle Scholar
Leibowitz, S.F., Roossin, P., Rosenn, M.Chronic norepinephrine injection into the hypothalamic paraventricular nucleus produces hyperphagia and increased body weight in the rat. Pharmacol Biochem Behav 1984 Nov;21(5):801–808CrossRefGoogle Scholar
Leslie, D.L., Rosenheck, R.A.Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004 Sep;161(9):1709–1711CrossRefGoogle Scholar
Lindenmayer, J.P., Nathan, A.M., Smith, R.C.Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;23(Suppl. 62):30–38Google Scholar
Masaki, T., Chiba, S., Yasuda, T., Noguchi, H., Kakuma, T., Watanabe, T.et al.Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004 Sep;53(9):2250–2260CrossRefGoogle Scholar
Masaki, T., Yoshimatsu, H., Chiba, S., Watanabe, T., Sakata, T.Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes 2001 Feb;50(2):385–391CrossRefGoogle Scholar
McIntyre, R.S., Mancini, D.A., Basile, V.S.Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001;23(Suppl. 62):23–29Google Scholar
Melkersson, K.Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 2004 Mar;14(2):115–119CrossRefGoogle Scholar
Melkersson, K.I., Dahl, M.L.Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003 Nov;170(2):157–166CrossRefGoogle Scholar
Melkersson, K.I., Hulting, A.L., Brismar, K.E.Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000 Oct;61(10):742–749CrossRefGoogle Scholar
Montague, C.T., Farooqi, I.S., Whitehead, J.P., Soos, M.A., Rau, H., Wareham, N.J.et al.Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997 Jun 26;387(6636):903–908CrossRefGoogle Scholar
Nasrallah, H.A.Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008 Jan;13(1):27–35CrossRefGoogle Scholar
Newcomer, J.W., Haupt, D.W., Fucetola, R., Melson, A.K., Schweiger, J.A., Cooper, B.P.et al.Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002 Apr;59(4):337–345CrossRefGoogle Scholar
Nilsson, T., Arkhammar, P., Rorsman, P., Berggren, P.O.Inhibition of glucose-stimulated insulin release by alpha 2-adrenoceptor activation is paralleled by both a repolarization and a reduction in cytoplasmic free Ca2+ concentration. J Biol Chem 1988 Feb 5;263(4):1855–1860Google Scholar
O’Neill, M.F.Unusual suspect for antipsychotic-induced diabetes. Drug Discov Today 2005 Oct 15;10(20):1338CrossRefGoogle Scholar
Peterson, H.R., Rothschild, M., Weinberg, C.R., Fell, R.D., McLeish, K.R., Pfeifer, M.A.Body fat and the activity of the autonomic nervous system. N Engl J Med 1988 Apr 28;318(17):1077–1083CrossRefGoogle Scholar
Pollmacher, T., Hinze-Selch, D., Mullington, J.Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996 Oct;16(5):403–409CrossRefGoogle Scholar
Popli, A.P., Konicki, P.E., Jurjus, G.J., Fuller, M.A., Jaskiw, G.E.Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997 Mar;58(3):108–111CrossRefGoogle Scholar
Ryan, M.C., Collins, P., Thakore, J.H.Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003 Feb;160(2):284–289CrossRefGoogle Scholar
Sakata, T., Ookuma, K., Fukagawa, K., Fujimoto, K., Yoshimatsu, H., Shiraishi, T.et al.Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation. Brain Res 1988 Feb 16;441(1–2):403–407CrossRefGoogle Scholar
Schotte, A., Janssen, P.F., Gommeren, W., Luyten, W.H., Van Gompel, P., Lesage, A.S.et al.Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996 Mar;124(1–2):57–73CrossRefGoogle Scholar
Seufert, J., Kieffer, T.J., Leech, C.A., Holz, G.G., Moritz, W., Ricordi, C.et al.Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 1999 Feb;84(2):670–676Google Scholar
Silvestre, J.S., Prous, J.Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005 Jun;27(5):289–304CrossRefGoogle Scholar
Sonnenberg, G.E., Krakower, G.R., Kissebah, A.H.A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004 Feb;12(2):180–186CrossRefGoogle Scholar
Spoelstra, J.A., Stolk, R.P., Cohen, D., Klungel, O.H., Erkens, J.A., Leufkens, H.G.et al.Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry 2004 May;65(5):674–678CrossRefGoogle Scholar
Sprouse, J.S., Reynolds, L.S., Braselton, J.P., Rollema, H., Zorn, S.H.Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology 1999 Nov;21(5):622–631CrossRefGoogle Scholar
Stumvoll, M., Goldstein, B.J., van Haeften, T.W.Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005 Apr;365(9467):1333–1346CrossRefGoogle Scholar
van Winkel, R., De Hert, M., Wampers, M., Van Eyck, D., Hanssens, L., Scheen, A.et al.Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008 Mar;69(3):472–479CrossRefGoogle Scholar
Wirshing, D.A., Wirshing, W.C., Kysar, L., Berisford, M.A., Goldstein, D., Pashdag, J.et al.Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999 Jun;60(6):358–363CrossRefGoogle Scholar
Zimmermann, U., Kraus, T., Himmerich, H., Schuld, A., Pollmacher, T.Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003 May–Jun;37(3):193–220CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.